The number of cases of cataract, myopia, fundus disease and other age-related eye diseases has been rapidly increased through the years. The concept of precision medicine has promoted the quick development of new ophthalmic drugs and therefore emerging need in conducting clinical trials for these innovations was observed to arise. Stem cell transplantation is considered to have a good therapeutic value for the treatment of retinal diseases. The United States and Japan regulatory agencies have approved several clinical trials in the field of retinal bioengineering to treat AMD and retinitis pigmentosa. From the other hand, Lucentis, Arbacicept and Conbercept became classic cases of VEGF targeted inhibitors successful application in ophthalmology. Stem cell replacement therapy as a modern trend in regenerative medicine is a prominent approach for future treatment of different diseases in Ophthalmology, for instance, corneal diseases and retinal diseases. From the other hand, Gene Therapy as a new direction has a greatest potential to cure genetic diseases with already identified pathogenic genes.

Proswell Medical Development Center Ophthalmology Team presented by senior and professional clinicians from ophthalmology field and senior level pharmacologists from R&D field. They are familiar with clinical diagnostic procedures and protocols of standard treatment for glaucoma, cataract, fundus disease etc. We have conducted over 20 ophthalmology clinical trials for such indications like dry eye, wet age-related macular degeneration, crystalline retinal degeneration, glaucoma, post cataract anti-inflammatory, allergic conjunctivitis, Bietti's crystalline dystrophy (recombinant adenovirus gene carrier for the treatment of rare disease in ophthalmology), uveitis, acquired blepharoptosis, etc., and covering all clinical trial phases, IIT and post marketing studies. The therapeutics administration methods include traditional eye drops and intravitreal injection, as well as subretinal injection required for lacrimal canalicular implantation and gene therapy. In terms of the long-term cooperation development approach, we have established a good cooperative relationship with many well-known local and overseas ophthalmology pharmaceutical companies and reputed industry experts.

Our ophthalmology dedicated medical team provides one stop medical service for all indications and all trial phases for the new investigational drugs, including but not limited to: CDP development, medical writing, Health Authority communication, protocol development, medical monitoring, and CSR development.